Cancer Research Cell Death Mechanisms and Cancer Therapy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 42, 2135-2138, June 1, 1982]
© 1982 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, M. C.

Characterization of the Lymphokine Responsible for Migration-inhibitory Activity against Tumor Cells1

Marion C. Cohen2

Department of Pathology, University of Connecticut Health Center, Farmington, Connecticut 06032

Lymphokine-containing supernatants have the ability to inhibit the migration of a variety of tumor cells in vitro in the absence of cytotoxic effects. In the present study, this tumor migration inhibition activity has been characterized in order to determine whether the responsible factor is the same or different from other known migration-inhibitory lymphokines. Since no preparations purified to homogeneity are generally available for these various factors, a variety of indirect procedures is necessary to make this determination. The profile of effects of monosaccharides, protease inhibitors, and neuraminidase on tumor migration inhibition factor, taken in conjunction with previously reported studies of other physicochemical and biological properties, provides evidence that tumor migration inhibition factor is distinct from both migration inhibition and leukocyte-inhibitory factor. A lymphokine with migration-inhibitory activity against tumor cells is a good candidtate for a variety of protective functions in vivo.

1 This work was supported by NIH Grant AI-12477.

2 To whom requests for reprints should be addressed.

Received 11/ 2/81. Accepted 2/26/82.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1982 by the American Association for Cancer Research.